Clinical TrialApr 27, 2026, 04:03 PM
ERAS-0015 Phase 1 shows robust efficacy in NSCLC (62% uORR) & PDAC (40% uORR)
AI Summary
Erasca, Inc. announced positive preliminary Phase 1 dose escalation data for its pan-RAS molecular glue ERAS-0015 in RAS-mutant solid tumors. The drug demonstrated robust monotherapy efficacy, with a 62% unconfirmed overall response rate (uORR) in 2L+ KRAS G12X NSCLC and 40% uORR in 2L KRAS G12X PDAC, comparing favorably to comparators. ERAS-0015 was generally well-tolerated, with mostly low-grade adverse events and no dose-limiting toxicities, and showed promising combinability with panitumumab.
Key Highlights
- ERAS-0015 showed 62% uORR in 2L+ KRAS G12X NSCLC at 16-32 mg QD PAD, exceeding comparator by 24 percentage points.
- ERAS-0015 achieved 75% uORR in post-ICI/platinum 2/3L KRAS G12X NSCLC at 16-32 mg QD PAD.
- ERAS-0015 demonstrated 40% uORR in 2L KRAS G12X PDAC at 16-32 mg QD PAD, exceeding comparator by 11 percentage points.
- At 32 mg QD, ERAS-0015 showed 50% uORR in 2L KRAS G12X PDAC, surpassing comparator by 15 percentage points.
- Monotherapy was generally well-tolerated with mostly low-grade adverse events, no DLTs, and no discontinuations due to TRAEs.
- Preliminary data suggest ERAS-0015 combines safely with panitumumab, with 1/1 uPR in CRC.
- Anticipated data disclosure for ERAS-0015 monotherapy and combination cohorts narrowed to H1 2027.